OrphanDrug
OrphanDrug
Pharma Knowledge Base

myelodysplastic syndrome with excess blasts-2

ORPHA: 100020

Contents

  1. 1. Overview
  2. 2. Available Treatments
  3. 3. Classification & Codes

Overview

myelodysplastic syndrome defined by 10-19% blasts in the bone marrow or 5-19% blasts in the blood and <10% blasts in the bone marrow. Approximately 33% of cases progress to acute leukemia. The prognosis is usually poor. (WHO)

Available Treatments (0)

No treatments linked yet

Clinical trials or compassionate use may be available — consult a specialist.

Classification & Codes

Orphanet Code

ORPHA:100020
myelodysplastic syndrome with excess blasts-2
OrphanetORPHA:100020
Treatments0 drug(s)
Statuspublished
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO
myelodysplastic syndrome with excess blasts-2 | OrphanDrug